GDUFA regulation self identified sites registered apis

According to the GDUFA regulation in place for companies with registrations in the US, our API production sites in Oss/The Netherlands (De Geer/Veersemeer and Moleneind/Kloosterstraat) have been self-identified according to FDA requirements.

The following APIs have been registered after the self-identification of our production sites:

* Ethinyl estradiol

* Estradiol micronized

* Naltrexone

* Norethindrone

* Norethindrone acetate

* Rocuronium bromide

The costs for GDUFA registration are being covered 100% by Aspen Oss, and will not be at the expense of customers filing these APIs at the FDA!